Bain Capital Life Sciences Investors

Latest statistics and disclosures from Bain Capital Life Sciences Investors's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are NUVL, NAMS, IRON, DNTH, PHVS, and represent 68.82% of Bain Capital Life Sciences Investors's stock portfolio.
  • Added to shares of these 7 stocks: IRON (+$22M), IPSC (+$14M), KYTX, MRNS, XLO, DNTH, CABA.
  • Started 1 new stock position in IPSC.
  • Reduced shares in these 6 stocks: MDGL (-$53M), NRIX (-$17M), ARQT (-$9.1M), ACRS, ANNX, CCCC.
  • Sold out of its positions in MDGL, NRIX.
  • Bain Capital Life Sciences Investors was a net seller of stock by $-42M.
  • Bain Capital Life Sciences Investors has $911M in assets under management (AUM), dropping by -26.80%.
  • Central Index Key (CIK): 0001703031

Tip: Access up to 7 years of quarterly data

Positions held by Bain Capital Life Sciences Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Bain Capital Life Sciences Investors

Bain Capital Life Sciences Investors holds 25 positions in its portfolio as reported in the June 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Nuvalent Inc-a (NUVL) 22.5 $205M 2.7M 75.86
 View chart
Newamsterdam Pharma Company Ordinary Shares (NAMS) 22.1 $201M 11M 19.21
 View chart
Disc Medicine (IRON) 8.9 $81M +36% 1.8M 45.07
 View chart
Dianthus Therapeutics (DNTH) 8.6 $78M 3.0M 25.88
 View chart
Pharvaris N V (PHVS) 6.8 $62M 3.3M 18.80
 View chart
Savara (SVRA) 6.4 $59M 15M 4.03
 View chart
Annexon (ANNX) 4.5 $41M -2% 8.4M 4.90
 View chart
Kyverna Therapeutics (KYTX) 2.8 $25M +6% 3.4M 7.50
 View chart
Tango Therapeutics (TNGX) 2.7 $25M 2.9M 8.58
 View chart
Solid Biosciences Com New (SLDB) 2.5 $23M 4.0M 5.67
 View chart
Mersana Therapeutics (MRSN) 1.9 $17M 8.7M 2.01
 View chart
Syros Pharmaceuticals Com New (SYRS) 1.6 $14M 2.7M 5.16
 View chart
Century Therapeutics (IPSC) 1.5 $14M NEW 5.4M 2.55
 View chart
Cabaletta Bio (CABA) 1.4 $12M +2% 1.6M 7.48
 View chart
X4 Pharmaceuticals (XFOR) 1.1 $9.8M 17M 0.58
 View chart
Arcutis Biotherapeutics (ARQT) 1.1 $9.6M -48% 1.0M 9.30
 View chart
Atea Pharmaceuticals (AVIR) 0.9 $8.2M 2.5M 3.31
 View chart
Rapid Micro Biosystems Class A Com (RPID) 0.6 $5.6M 8.4M 0.66
 View chart
C4 Therapeutics Com Stk (CCCC) 0.6 $5.1M -2% 1.1M 4.62
 View chart
Nautilus Biotechnology (NAUT) 0.5 $4.7M 2.0M 2.34
 View chart
Xilio Therapeutics (XLO) 0.4 $3.6M +34% 3.8M 0.95
 View chart
Marinus Pharmaceuticals Com New (MRNS) 0.3 $2.7M +62% 2.3M 1.17
 View chart
Adagio Therapeutics (IVVD) 0.2 $2.0M 1.8M 1.10
 View chart
Aclaris Therapeutics (ACRS) 0.1 $1.1M -66% 1.0M 1.10
 View chart
Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) 0.1 $872k 100k 8.72
 View chart

Past Filings by Bain Capital Life Sciences Investors

SEC 13F filings are viewable for Bain Capital Life Sciences Investors going back to 2017

View all past filings